| The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review A Fabbri, A Lai, Q Grundy, LA Bero American journal of public health 108 (11), e9-e16, 2018 | 229 | 2018 |
| Defining and conceptualising the commercial determinants of health AB Gilmore, A Fabbri, F Baum, et al The Lancet, 2023 | 214 | 2023 |
| The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures L Bero, N Chartres, J Diong, A Fabbri, D Ghersi, J Lam, A Lau, ... Systematic Reviews 7 (1), 242, 2018 | 213 | 2018 |
| Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis N Chartres, A Fabbri, LA Bero JAMA Internal Medicine 176 (12), 1769-1777, 2016 | 93 | 2016 |
| Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries MB Fabbri A, Santos A, Mezinska S, Mulinari S International Journal of Health Policy and Management 7 (6), 504-509, 2018 | 81 | 2018 |
| Industry funding of patient and health consumer organisations: systematic review with meta-analysis A Fabbri, L Parker, C Colombo, et al. BMJ 368, 2020 | 63 | 2020 |
| Food industry sponsorship of academic research: investigating commercial bias in the research agenda A Fabbri, TJ Holland, LA Bero Public health nutrition 21 (18), 3422-3430, 2018 | 49 | 2018 |
| Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies’ websites A Fabbri, G Gregoraci, D Tedesco, F Ferretti, F Gilardi, D Iemmi, C Lisi, ... BMJ open 6 (6), e011124, 2016 | 47 | 2016 |
| Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization guidelines (2009–2017) S McDonald, A Fabbri, L Parker, J Williams, L Bero International Health, 2019 | 31 | 2019 |
| A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia A Fabbri, Q Grundy, B Mintzes, S Swandari, R Moynihan, E Walkom, ... BMJ open 7 (6), e016701, 2017 | 31 | 2017 |
| Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity A Fabbri, N Chartres, G Scrinis, LA Bero Public health nutrition 20 (7), 1306-1313, 2017 | 31 | 2017 |
| Comparative analysis of medicines safety advisories released by Australia, Canada, the United States, and the United Kingdom LT Perry, A Bhasale, A Fabbri, J Lexchin, L Puil, M Joarder, B Mintzes JAMA internal medicine 179 (7), 982-984, 2019 | 30 | 2019 |
| Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study B Mintzes, S Swandari, A Fabbri, Q Grundy, R Moynihan, L Bero BMJ Open 8 (2), e019027, 2018 | 28 | 2018 |
| Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis A Fabbri, S Swandari, E Lau, A Vitry, B Mintzes International Journal of Health Services 49 (2), 273-293, 2019 | 25 | 2019 |
| “Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study L Parker, A Fabbri, Q Grundy, B Mintzes, L Bero BMJ 367, l6694, 2019 | 23 | 2019 |
| Global Media Coverage of the Benefits and Harms of Early Detection Tests M O’Keeffe, A Barratt, A Fabbri, JR Zadro, GE Ferreira, S Sharma, ... JAMA Internal Medicine 181 (6), 865-867, 2021 | 18 | 2021 |
| The inclusion of nurses in pharmaceutical industry–sponsored events: guess who is also coming to dinner? Q Grundy, A Fabbri, B Mintzes, S Swandari, L Bero JAMA Internal Medicine 176 (11), 1718-1720, 2016 | 18 | 2016 |
| Corporate Political Activity: Taxonomies and Model of Corporate Influence on Public Policy. S Ulucanlar, K Lauber, A Fabbri, B Hawkins, M Mialon, L Hancock, ... International Journal of Health Policy and Management, 2023 | 17 | 2023 |
| Pharmaceutical industry payments to leaders of professional medical associations in Australia. Focus on cardiovascular disease and diabetes EA Karanges, N Ting, L Parker, A Fabbri, L Bero AJGP 49 (3), 151-154, 2020 | 16 | 2020 |
| A Descriptive Analysis of Medicines Safety Advisories issued by National Medicines Regulators in Canada, Australia, the United Kingdom and the United States - 2007 to 2016. L Perry, A Bhasale, A Fabbri, J Lexchin, L Puil, M Joarder, B Mintzes Pharmacoepidemiology and Drug Safety, 2020 | 16 | 2020 |
